Update: Erytech has upgraded its projected IPO to $125M by offering more shares than originally planned.
Originally published 09/10/2017
Erytech has filed for an IPO on the Nasdaq Global Market and a private placement on Euronext Paris while preparing for its first product approval.
Erytech, based in Lyon, is developing a unique technology based on encapsulating drugs in red blood cells. The company has now announced the launch of a global offering to raise funds through an initial public offering of up to $100M (€85M) on the Nasdaq Global Market under the ticker “ERYP” and a private placement of shares, of an undisclosed amount, on Euronext Paris.
Both offerings seem to be timed with upcoming meetings with the FDA and the EMA’s CHMP to discuss the design of a Phase III study for its lead candidate, eryaspase, in pancreatic cancer. In addition, Erytech is preparing to resubmit for the European approval of eryaspase to treat relapsed or refractory acute lymphoblastic leukemia (ALL) after the first was withdrawn when the EMA requested additional data.
Erytech’s GRASPA, the commercial name for eryaspase in Europe and Israel, consists of the enzyme L-asparaginase encapsulated within donor-derived red blood cells. The enzyme depletes the amino acid asparagine from the bloodstream to starve the tumor cells that, unlike healthy cells, cannot produce their own asparagine. The treatment is under development to treat ALL, pancreatic cancer, acute myeloid leukemia (AML) and solid tumors.
Image via zhaoliang70 /Shutterstock
This awesome article Update: French Red Blood Cell Biotech Aims Higher for $125M Nasdaq IPO appeared first on Labiotech.eu. Be kind and don’t copy it without asking 😉
The FDA has granted orphan drug designation to Shire’s hemophilia A gene therapy, giving it the boost it needs to catch up with others in the field. Shire specializes in the development of drugs for rare diseases, including hemophilia A …
This awesome article Shire’s Hemophilia Gene Therapy Boosted by Orphan Drug Designation appeared first on Labiotech.eu. Be kind and don’t copy it without asking 😉
TiGenix has seen its Crohn’s disease candidate receive orphan drug designation after agreeing on a global Phase III trial. TiGenix exploits the anti-inflammatory properties of donor-derived stem cells to treat diseases. One of its candidates, Cx601, is targeted at Crohn’s disease – …
This awesome article FDA Grants Belgian Crohn’s Disease Candidate Orphan Designation appeared first on Labiotech.eu. Be kind and don’t copy it without asking 😉
The Human Cell Atlas will map all of the cells in the body, and the Chan Zuckerberg Initiative has given a grant to Swedish researchers to join the project. Mark Zuckerberg and his wife, Priscilla Chan, founded the Chan Zuckerberg …
This awesome article Swedish Human Cell Atlas gets the Support of Chan & Zuckerberg appeared first on Labiotech.eu. Be kind and don’t copy it without asking 😉
Da Volterra has been boosted by a €20M loan to speed up the development of solutions for the antibiotic resistance crisis. The French biopharma concentrates on the prevention and treatment of serious infections. This is a big area of interest due …
This awesome article EU gives French Biotech €20M to Continue the Fight Against Antibiotic Resistance appeared first on Labiotech.eu. Be kind and don’t copy it without asking 😉